The Association Between Breast Cancer and Blood-Based Methylation of \textit{CD160}, \textit{ISYNA1} and \textit{RAD51B} in the Chinese Population

Chunlan Liu\textsuperscript{1}, Xiajie Zhou\textsuperscript{1}, Jialie Jin\textsuperscript{1}, Qiang Zhu\textsuperscript{1}, Lixi Li\textsuperscript{2}, Qiming Yin\textsuperscript{1}, Tian Xu\textsuperscript{3}, Wanjian Gu\textsuperscript{3}, Fei Ma\textsuperscript{2} and Rongxi Yang\textsuperscript{1*}

\textsuperscript{1}Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, China, \textsuperscript{2}Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, \textsuperscript{3}Department of Clinical Laboratory, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China

Recent studies have identified DNA methylation signatures in the white blood cells as potential biomarkers for breast cancer (BC) in the European population. Here, we investigated the association between BC and blood-based methylation of cluster of differentiation 160 (\textit{CD160}), inositol-3-phosphate synthase 1 (\textit{ISYNA1}) and \textit{RAD51} paralog B (\textit{RAD51B}) genes in the Chinese population. Peripheral blood samples were collected from two independent case-control studies with a total of 272 sporadic early-stage BC cases (76.5\% at stage I&II) and 272 cancer-free female controls. Mass spectrometry was applied to quantitatively measure the levels of DNA methylation. The logistic regression and non-parametric tests were used for the statistical analyses. In contrast to the protective effects reported in European women, we reported the blood-based hypomethylation in \textit{CD160}, \textit{ISYNA1} and \textit{RAD51B} as risk factors for BC in the Chinese population (\textit{CD160}\_CpG\_3, \textit{CD160}\_CpG\_4/cg20975414, \textit{ISYNA1}\_CpG\_2, \textit{RAD51B}\_CpG\_3 and \textit{RAD51B}\_CpG\_4; odds ratios (ORs) per -10\% methylation ranging from 1.08 to 1.67, \(p < 0.05\) for all). Moreover, hypomethylation of \textit{CD160}, \textit{ISYNA1} and \textit{RAD51B} was significantly correlated with age, BC subtypes including estrogen receptor (ER)-negative BC tumors, triple negative tumors, BC cases with larger size, advanced stages and more lymph node involvement. Our results supported the report in European women that BC is associated with altered methylation of \textit{CD160}, \textit{ISYNA1} and \textit{RAD51B} in the peripheral blood, although the effects are opposite in the Chinese population. The difference between the two populations may be due to variant genetic background or life styles, implicating that the validations of epigenetic biomarkers in variant ethnic groups are warranted.

Keywords: breast cancer, DNA methylation, cluster of differentiation 160 gene, inositol-3-phosphate synthase 1 gene, \textit{RAD51} paralog B gene
INTRODUCTION

Breast cancer (BC) is the most commonly diagnosed cancer among women worldwide, with an estimated 2.3 million new cases in 2020 (Sung et al., 2021). Despite therapeutic advances in chemotherapy, radiotherapy, hormone and targeted therapies, BC remains the leading cause of cancer mortality among females globally (Sung et al., 2021). Mammography is currently the most widely-used screening tool for the detection of BC, which is estimated to decrease BC mortality by 20–40% (Berry et al., 2005; Seely and Alhassan, 2018). However, the benefit of mammography for women aged 40 to 49 with dense breast tissue is uncertain (Moss et al., 2015). In addition, the radiological exposure, false-positive results and overdiagnosis are limitations of concern (Independent United Kingdom Panel on Breast Cancer Screening, 2012; Pace and Keating, 2014). Thus, the identification of new reliable markers for the early detection and/or risk stratification of BC is urgently needed.

Epigenetic modifications are heritable and can alter gene expression without changes in the DNA sequence (Jones and Baylin, 2002; Feinberg, 2004). Epigenetic abnormalities, particularly aberrant DNA methylation events, are critical factors for the initiation and progression of human cancers (Jones and Baylin, 2002; Grady et al., 2021). Hypermethylation in the promoter regions of tumor suppressor genes and global hypomethylation have been recognized as the early events in almost every cancer type such as breast (Umbricht et al., 2001), lung (Belinsky et al., 1998), and colon cancer (Rademakers et al., 2021). Previous studies have found DNA methylation alterations in circulating free DNA (cfDNA) of BC patients (Fackler et al., 2014; Mahon et al., 2014; Sun et al., 2015; Matsui et al., 2016; Uehiro et al., 2016). Recently, several investigations have identified DNA methylation signatures in the white blood cells as potential biomarkers for the detection of BC, but were mostly limited by low statistical power (Iwamoto et al., 2011; Brennan et al., 2012; Cappetta et al., 2021). Yang et al. (Yang et al., 2020) have developed a new methodology using genome-wide association study (GWAS) data to evaluate the DNA methylation levels at adjacent CpG sites, and identified 450 BC-associated CpGs. By integrative analysis of genetic variations, DNA methylation and gene expression data, they found that 38 CpGs in 21 genes could affect BC via regulating gene expression. Since DNA methylation patterns are influenced by genetic backgrounds or life styles (Zhang et al., 2011; Wu et al., 2020; Rasmussen et al., 2021), it would be meaningful to validate the associations between BC and methylation of these 21 genes in other ethnic groups especially via a quantitative assay. Hereby, we performed MassARRAY to quantitatively evaluate methylation-altered genes in the peripheral blood DNA that are associated with BC risk in two independent case-control studies with a total of 272 sporadic BC cases and 272 cancer-free female controls in the Chinese population.

MATERIALS AND METHODS

Study Population

This study was approved by the Ethics Committee of Nanjing Medical University, the Cancer Hospital of Chinese Academy of Medical Science and Jiangsu Province Hospital of Chinese
Medicine in China. All the recruited participants provided written informed consent. The diagnosis of BC was confirmed by pathology, and all peripheral blood samples were collected before surgery and any BC related treatment. All the female controls have normal blood cell counts and have claimed no history of tumor or autoimmune disease. No further inclusion criteria were applied during recruitment of controls.

Validation I: A total of 48 sporadic BC cases with a median age of 44 years (34–50 years old) were collected at the Cancer Hospital of Chinese Academy of Medical Science from 2015 to 2018. Forty-eight age-matched female controls (median age: 44 years, range from 28 to 65 years) were consecutively collected from the physical examination center at Jiangsu Province Hospital of Chinese Medicine in 2018.

Validation II: A total of 224 sporadic BC cases with a median age of 46 years (35–73 years old) were collected at the Cancer Hospital of Chinese Academy of Medical Science from 2015 to 2018. In addition, 224 age-matched cancer-free female controls (median age: 46 years, range from 25 to 78 years) were randomly recruited from the physical examination center at Jiangsu Province Hospital of Chinese Medicine in 2018.

Sample Processing and Bisulfite Conversion
Peripheral blood samples from BC cases and controls were collected by ethylene diamine tetraacetic acid (EDTA) tubes. The blood samples were kept at 4°C for less than 24 h and further stored at −80°C till usage. Genomic DNA was isolated from peripheral whole blood using the DNA Extraction Kit (TANTICA, Nanjing, China), and then bisulfite converted by EZ-96 DNA Methylation Gold Kit (Zymo Research, Orange County, United States) according to the manufacturer's protocol. After bisulfite treatment, all non-methylated cytosine (C) bases in CpG sites were converted to uracil (U), whereas all methylated C bases remained C. The samples from BC cases and controls were processed in parallel.

Selection of Methylated Gene Markers
To validate the 21 methylation-altered genes that are associated with BC risk reported by Yang et al. (Yang et al., 2020), we applied the following exclusion criteria to select the CpG sites: 1) referred CpGs located at 10 kb away from the genomic regions; 2) single nucleotide polymorphisms (SNPs) overlapped with CpG sites; 3) amplicons could not be designed across the referred CpGs; 4) primer design failed; and 5) methylation intensities of CpG sites are not in the accuracy range of mass spectrometry (methylation intensity <0.05 or >0.95) (Figure 1).

Six genes (GBA, ATG10, TRIM27, CD160, ISYNA1, RAD51B) were filtered out for the validation I with 48 sporadic BC cases and 48 matched cancer-free female controls. Three genes (CD160, ISYNA1, RAD51B) that showed significant difference in methylation levels between BC cases and controls in validation I were further filtered out for the validation II with 224 sporadic BC cases and 224 matched female controls (Figure 1).
### Matrix-Assisted Laser Desorption/Ionization Time-Of-Flight Mass Spectrometry

The methylation levels of CpG sites were quantitatively determined by MALDI-TOF mass spectrometry (Agena Bioscience, San Diego, California, United States). The cg20975414 (chr1: 145,715,572) and cg12832565 (chr1: 145,715,673) loci in CD160 gene reported by Yang et al. are located at the promoter region of CD160. We therefore designed an amplicon (498 bp, chr1: 145,715,317–145,715,815) harboring both cg20975414 and cg12832565 loci and flanking four CpG sites. This amplicon covers the promoter region and exon 1 of CD160, as well as part of intron 1. The cg22161383 (chr1: 145,715,673) located at intron 8 of RAD51B, and CD160_CpG_6/cg13803234 (chr1: 145,715,673) covering both cg13803234 and cg10975863. The ISYNA1 gene reported by Yang et al. is located at chr1: 45,715,673, n = 272). The amplicon (454 bp, chr1: 145,715,317–145,715,815) harboring both cg22161383 and cg12832565 loci and flanking four CpG sites. This amplicon covers the promoter region and exon 1 of CD160, as well as part of intron 1. The cg22161383 (chr1: 145,715,673) located at intron 8 of ISYNA1. An amplicon (454 bp, chr1: 145,715,317–145,715,815) harboring both cg22161383 and cg12832565 loci and flanking six CpG sites was designed. The cg13803234 (chr1: 68,830,813) and cg10975863 (chr1: 68,830,704) loci in RAD51B gene reported by Yang et al. are located at intron 8 of RAD51B. We therefore designed an amplicon (478 bp, chr1: 68,830,515–68,830,993, at intron 8 of RAD51B) covering both cg13803234 and cg10975863. The sequences of amplicons are presented in Supplementary Figure S1. Briefly, the bisulfite-converted genomic DNA was amplified by bisulfite-specific primers. There were no SNPs located at the primer regions or overlapped with the CpG sites. Following shrimp alkaline phosphatase cleanup, T cleavage, and Clean Resin steps, the final products were transferred to a SpectroCHIP G384 by a Nanodispenser RS1000 apparatus (Agena, United States) and then the chips were detected by MassARRAY spectrometry. The quantitative methylation levels of each CpG site or aggregate of multiple CpG sites were collected by SpectroACQUIRE v3.3.1.3 software and visualized by EpiTyper v1.3 software. The EpiTyper v1.3 software automatically calculate methylation levels of each CpG locus in the investigated amplicon by comparing the signal intensities of methylated and non-methylated segments.

### Statistical Analyses

All the statistical data were analyzed using SPSS 25.0 software (SPSS Inc., Chicago, United States). The individual CpG site differences between two or three groups were assessed by non-parametric tests. The methylation differences between the cases and controls were analyzed by binary logistic regression. The dependent variable was the status of existence of disease (case = 1, control = 0), the independent variable was the DNA methylation levels of each CpG site. The covariates were adjusted, including age and batches of different measurements. A two-tailed p value <0.05 was considered statistically significant.
RESULTS

Validation of Breast Cancer-Associated DNA Methylation Markers in the Peripheral Blood

After exclusion criteria were applied, six genes (GBA, ATG10, TRIM27, CD160, ISYNA1, RAD51B) were selected for validating the associations between DNA methylation and BC with MassARRAY EpiTyper assays in validation I (48 sporadic BC cases and 48 matched cancer-free female controls) (Supplementary Table S1). Among them, three genes (CD160, ISYNA1, RAD51B) showed methylation differences between BC cases and controls (Supplementary Table S1). Thus, these three genes were further validated in 224 sporadic BC cases and 224 matched female controls (validation II). Combining two validation studies with a total of 272 sporadic BC cases and 272 cancer-free female controls, we identified the blood-based hypomethylation in CD160, ISYNA1, and RAD51B as risk factors for BC in the Chinese population (CD160_CpG_3, CD160_cg20975414, ISYNA1_CpG_2, RAD51B_CpG_3 and RAD51B_CpG_4; odds ratios (ORs) per -10% methylation ranging from 1.08 to 1.67, $p < 0.05$ for all, by logistic regression adjusting for age and batch effects, Figure 2, Table 1).

Combination Analyses of the Association Between Blood-Based Methylation of CD160, ISYNA1 and RAD51B and Breast Cancer Stratified by Age

Since age has impact on DNA methylation patterns (Horvath et al., 2012), we next evaluated the relationship between the methylation levels of CD160, ISYNA1 and RAD51B and age in 272 sporadic BC cases and 272 cancer-free female controls combining validation I and validation II. As shown in Supplementary Table S2, the methylation levels of CD160_CpG_2, CD160_CpG_3 and CD160_CpG_5 were inversely correlated with age in controls (Spearman rho = −0.191, −0.150 and −0.146, respectively), whereas methylation levels of CD160_CpG_3 were inversely correlated with age in BC cases (Spearman rho = −0.240). In ISYNA1, only CpG_2 showed significantly positive correlation with age in BC cases (Spearman rho = 0.211). In RAD51B, cg13803234 showed positive correlation with age both in controls and in BC cases (Spearman rho = 0.224 and 0.195, respectively, Supplementary Table S2).

Since CD160, ISYNA1 and RAD51B showed differential age-related methylation patterns in controls and BC cases, we further stratified the subjects by 45 years old according to the median age combining two validation studies. In women younger than 45 years, CD160_CpG_5 and ISYNA1_CpG_2 showed significantly lower methylation levels in the BC cases than in the controls (ORs per -10% methylation = 1.21 and 1.26 respectively, $p < 0.008$ for both by logistic regression adjusted for age and batch effects, Figure 3A, Table 2), whereas ISYNA1_CpG_4 was hypermethylated in BC cases (OR per -10% methylation = 0.72, $p = 0.023$ by logistic regression, Figure 3A, Table 2). In the group ≥45 years, hypomethylation of CD160_CpG_3 and RAD51B_CpG_3 were significantly associated with increased risk of BC (ORs per -10% methylation = 1.16 and 2.31 respectively, $p < 0.015$ for both by logistic regression adjusted for age and batch effects, Figure 3B, Table 3).

Combination Analyses of the Correlation Between Altered Methylation in CD160, ISYNA1 and RAD51B and Clinical Characteristics of Breast Cancer

Next, the relationship between CD160, ISYNA1 and RAD51B methylation and the clinical characteristics of 272 sporadic BC cases was investigated. Lower methylation of CD160_CpG_5 and CD160_CpG_7 were observed in HER2-negative BC tumors and in triple negative tumors, respectively ($p < 0.05$, Table 4). The BC cases with advanced stages (stage II and stage III), larger tumor size (T2&T3&T4), and more lymph node involvement (pN1&pN2&pN3) had lower ISYNA1_cg22161383 methylation than the patients with stage 0&I tumor, smaller tumor (T0&T1),
and no lymph node involvement ($p < 0.019$, Table 5). In RAD51B, CpG_6 and CpG_20 showed lower methylation levels in BC patients with more lymph node involvement ($p$N1pN2pN3) ($p = 0.001$ for both; Table 6). Additionally, hypomethylation of RAD51B_CpG_1,2, RAD51B_CpG_3 and RAD51B_cg13803234 was correlated with ER-negative status, hypomethylation of RAD51B_CpG_1,2 was correlated with PR-negative status, and hypomethylation of RAD51B_CpG_1,2, RAD51B_CpG_3, RAD51B_cg13803234, RAD51B_CpG_10, RAD51B_CpG_11 and RAD51B_CpG_18 was correlated with triple-negative BC ($p < 0.05$, Table 6). Other CpG sites in CD160, ISYNAI and RAD51B showed no or borderline correlations with clinical characteristics of BC.

**DISCUSSION**

Yang et al. (Yang et al., 2020) have reported BC-related methylation in peripheral blood in the European population. Here, we validated the associations in the Chinese population in two independent case-control studies with a total of 544 subjects. Our results supported the previous findings (Yang et al., 2020) that altered methylation of CD160, ISYNAI and RAD51B in the peripheral blood was associated with BC.

CD160, ISYNAI and RAD51B have been involved in the development of various types of cancer. CD160 (cluster of differentiation 160), also known as natural killer cell receptor BY55, plays a role in human cancers such as chronic lymphocytic leukemia (CLL) (Bozorgmehr et al., 2021), colon cancer and melanoma (Chabot et al., 2011; Saleh et al., 2020), and pancreatic cancer (Liu et al., 2020). Bozorgmehr et al. (Bozorgmehr et al., 2021) found that CD160 was upregulated in patients with CLL and its expression was associated with an exhausted T cell phenotype, implicating an important role of CD160 in T cell exhaustion in patients with CLL. Chabot et al. (Chabot et al., 2011) found overexpression of CD160 on endothelial cells of newly formed blood vessels in human colon cancer and mouse B16 melanoma, but not in vessels of healthy tissues, suggesting its potential roles in the development and progression of cancer. Liu et al. (Liu et al., 2020) observed that tumor-infiltrating CD8+ T cells were significantly enriched with the CD160+ subset in pancreatic cancer patients, and patients with higher frequencies of tumor CD160+CD8+ T cells presented lower survival. Farren and colleagues have shown that the CD160 is overexpressed in malignant B cells, but not in healthy B cells, indicating CD160 as a tumor-specific marker of malignant B lymphocytes (Farren et al., 2011). ISYNAI (inositol-3-phosphate synthase1) is a rate-limiting enzyme that catalyzes the biosynthesis of inositol, which regulates glycolipid metabolism, neurotrophic effects and tumor suppression (Croze and Soulage, 2013). Activated p53 could regulate ISYNAI expression in the cells, and knockdown of ISYNAI caused resistance to adriamycin treatment,
Yang et al. (Yang et al., 2020) have shown that DNA methylation levels of RAD51B are positively correlated with BC risk in the European population. The differential DNA methylation patterns between ethnicities have been reported previously, including significant differences in global leukocyte DNA methylation by race/ethnicity (Zhang et al., 2011), differences in smoking-associated DNA methylation patterns in South Asians and Europeans (Elliott et al., 2014), as well as race-specific alterations in DNA methylation among African Americans and Caucasians (Chitrala et al., 2020). The major mechanism for the epigenetic related hereditary background is the differential genetic variations and frequencies in different populations. Genetic studies have identified ethnic differences in gene polymorphisms of CD160 in autoimmune diseases and RAD51B in BC (Hua et al., 2012; Kurreeman et al., 2012; Zhu et al., 2016; Li et al., 2018; He et al., 2021). Although so far there are no studies about the variations of ISYNA1 in different ethnic groups, the upstream genetic variations may modulate the regulation of ISYNA1. Indeed, the methylation-expression of ISYNA1 is regulated by P53 (Koguchi et al., 2016), and different mutations in P53 gene have been reported in BC among different ethnic groups (Huo et al., 2017). On the other hand, environmental exposures and life styles may contribute to differences in DNA methylation as well (Delgado-Cruzata et al., 2015; Abdul et al., 2017; Nwanaji-Enwerem and Colicino, 2020; Wang et al., 2020). For example, the environmental carcinogen pollutions, such as compounds in

### Table 3: Association between blood-based methylation of CD160, ISYNA1, and RAD51B and BC in subjects older than or equal to 45 years old combining validation I and validation II.

| CpG sites | Controls (n = 141) | BC cases (n = 156) | OR (95% CI)* | p-value* |
|-----------|-------------------|-------------------|--------------|---------|
| CD160_CpG_2 | 0.92 (0.81–0.98) | 0.96 (0.83–0.98) | 1.12 (0.93–1.35) | 0.215 |
| CD160_CpG_3 | 0.83 (0.61–1.00) | 0.75 (0.54–1.00) | 1.16 (1.04–1.30) | **0.010** |
| CD160_CpG_4/cg20675414 | 0.49 (0.32–0.63) | 0.46 (0.24–0.69) | 1.08 (0.96–1.21) | 0.207 |
| CD160_CpG_5 | 0.65 (0.48–0.82) | 0.70 (0.46–0.86) | 1.01 (0.91–1.13) | 0.864 |
| CD160_CpG_6/cg12832565 | 0.43 (0.31–0.59) | 0.46 (0.27–0.64) | 0.97 (0.87–1.09) | 0.654 |
| CD160_CpG_7 | 0.69 (0.55–0.83) | 0.70 (0.50–0.82) | 1.08 (0.86–1.32) | 0.247 |
| ISYNA1_CpG_1 | 0.84 (0.79–0.89) | 0.85 (0.80–0.90) | 1.05 (0.78–1.40) | 0.756 |
| ISYNA1_CpG_2 | 0.69 (0.61–0.77) | 0.68 (0.58–0.81) | 1.03 (0.89–1.19) | 0.705 |
| ISYNA1_CpG_3 | 0.87 (0.81–0.92) | 0.88 (0.78–0.92) | 1.00 (0.74–1.36) | 0.986 |
| ISYNA1_CpG_4/cg22181383 | 0.86 (0.81–0.91) | 0.87 (0.78–0.93) | 1.04 (0.80–1.35) | 0.771 |
| ISYNA1_CpG_6 | 0.34 (0.25–0.42) | 0.33 (0.22–0.40) | 1.05 (0.88–1.25) | 0.628 |
| ISYNA1_CpG_7 | 0.55 (0.48–0.64) | 0.56 (0.48–0.66) | 0.97 (0.81–1.18) | 0.784 |
| ISYNA1_CpG_9 | 0.54 (0.44–0.62) | 0.56 (0.47–0.66) | 0.89 (0.75–1.05) | 0.164 |
| RAD51B_CpG_1,2 | 0.66 (0.62–0.70) | 0.65 (0.61–0.69) | 0.98 (0.62–1.54) | 0.919 |
| RAD51B_CpG_3 | 0.97 (0.95–0.99) | 0.96 (0.93–0.99) | 2.31 (1.18–4.53) | 0.015 |
| RAD51B_CpG_4 | 0.69 (0.55–0.82) | 0.65 (0.51–0.79) | 1.12 (0.90–1.26) | 0.068 |
| RAD51B_CpG_6 | 0.66 (0.55–0.76) | 0.67 (0.56–0.78) | 0.97 (0.83–1.13) | 0.701 |
| RAD51B_CpG_7,8/cg13803234 | 0.88 (0.76–1.00) | 0.87 (0.77–1.00) | 0.91 (0.77–1.08) | 0.275 |
| RAD51B_CpG_9 | 0.58 (0.50–0.67) | 0.58 (0.48–0.67) | 1.08 (0.90–1.28) | 0.409 |
| RAD51B_CpG_10 | 0.38 (0.29–0.47) | 0.39 (0.28–0.48) | 0.96 (0.82–1.11) | 0.564 |
| RAD51B_CpG_11 | 0.32 (0.25–0.40) | 0.32 (0.25–0.40) | 0.94 (0.77–1.14) | 0.509 |
| RAD51B_CpG_12 | 0.36 (0.26–0.44) | 0.37 (0.29–0.47) | 0.93 (0.78–1.10) | 0.401 |
| RAD51B_CpG_13,14/cg10975863 | 0.48 (0.37–0.59) | 0.48 (0.39–0.59) | 0.99 (0.85–1.16) | 0.940 |
| RAD51B_CpG_15 | 0.34 (0.25–0.41) | 0.33 (0.26–0.43) | 0.93 (0.79–1.10) | 0.384 |
| RAD51B_CpG_16 | 0.27 (0.18–0.37) | 0.28 (0.15–0.36) | 1.04 (0.89–1.21) | 0.625 |
| RAD51B_CpG_18 | 0.49 (0.37–0.62) | 0.50 (0.39–0.63) | 0.96 (0.84–1.10) | 0.602 |
| RAD51B_CpG_20 | 0.66 (0.55–0.77) | 0.67 (0.56–0.78) | 0.98 (0.84–1.14) | 0.780 |

*Logistic regression adjusted for age and different batches for the measurements. Bold values indicated p < 0.05.
comprehension gases and in cigarette smoke generally cause global DNA hypomethylation (but hypermethylate the tumor suppressor genes), increasing the likelihood of cancers, including BC (Xue et al., 2011; Lee and Pausova, 2013; Goldvasser et al., 2017; Martin and Fry, 2018). Moreover, the lifestyle habits including diets that are abundant in xenoestrogens and nutrition influences global DNA methylation and is inflammato and chemo-preventive, consumption of inflammatory and carcinogen foods or anti-inflammatory in cases. Significant dna methylation alterations, once established, can persist in the absence of the initial environmental or lifestyle factors. However, due to the limitation of hospital-based sample collection, the environmental factors and life style factors such as smoking habits and diets were unfortunately not available in this study. Further analyses including information of lifestyle and environmental factors in future studies with larger sample size are warranted. Taken together, genetic background and different lifestyle styles and environmental factors in future studies are warranted. Differential expression of CD160, ISYNA1 and RAD51B in cases than controls were further found in women of different age groups. Our results suggested that age might be a confounder for the cancer associated aberrant methylation of CD160, ISYNA1 and RAD51B in the blood. To better understand the role of age on the blood-based methylation changes, further mechanism studies of CD160, ISYNA1 and RAD51B and aging is warranted in the future.

Our data revealed that DNA methylation was related to the clinical characteristics of BC, consistent with our previous studies (Lei et al., 2021; Yin et al., 2022). Here we found significantly lower methylation of CD160, ISYNA1 and RAD51B in cases than controls were further found in women of different age groups. Our results suggested that age might be a confounder for the cancer associated aberrant methylation of CD160, ISYNA1 and RAD51B in the blood. To better understand the role of age on the blood-based methylation changes, further mechanism studies of CD160, ISYNA1 and RAD51B and aging is warranted in the future.

Our data revealed that DNA methylation was related to the clinical characteristics of BC, consistent with our previous studies (Lei et al., 2021; Yin et al., 2022). Here we found significantly lower methylation of CD160, ISYNA1 and RAD51B in cases than controls were further found in women of different age groups. Our results suggested that age might be a confounder for the cancer associated aberrant methylation of CD160, ISYNA1 and RAD51B in the blood. To better understand the role of age on the blood-based methylation changes, further mechanism studies of CD160, ISYNA1 and RAD51B and aging is warranted in the future.

Our data revealed that DNA methylation was related to the clinical characteristics of BC, consistent with our previous studies (Lei et al., 2021; Yin et al., 2022). Here we found significantly lower methylation of CD160, ISYNA1 and RAD51B in cases than controls were further found in women of different age groups. Our results suggested that age might be a confounder for the cancer associated aberrant methylation of CD160, ISYNA1 and RAD51B in the blood. To better understand the role of age on the blood-based methylation changes, further mechanism studies of CD160, ISYNA1 and RAD51B and aging is warranted in the future.

TABLE 4 | Correlation between CD160 methylation and the clinical characteristics of sporadic BC cases combining validation I and validation II.

| Characteristics | Group (n) | Correlation between CD160 methylation and clinical characteristics | Median of methylation levels |
|-----------------|----------|---------------------------------------------------------------|-----------------------------|
| Tumor stage     |          |                                                               | CD160_CpG_2 | CD160_CpG_3 | CD160_CpG_4/ | CD160_CpG_5 | CD160_CpG_6/ | CD160_CpG_7 |
|                 |          |                                                               |              |              | cg20975414   |              | cg12832565   |              |
| Stage 0&I (116) |          |                                                               | 0.96         | 0.85         | 0.42         | 0.71         | 0.49         | 0.72         |
| Stage II&III (131) |          |                                                               | 0.96         | 0.87         | 0.47         | 0.63         | 0.47         | 0.71         |
| p-value*        |          |                                                               | 0.583        | 0.849        | 0.705        | 0.257        | 0.759        | 0.560        |
| Tumor size      |          |                                                               | 0.96         | 0.85         | 0.43         | 0.66         | 0.49         | 0.71         |
| T0&1 (158)      |          |                                                               | 0.97         | 0.88         | 0.47         | 0.66         | 0.44         | 0.71         |
| T2&3&4 (91)     |          |                                                               | 0.590        | 0.539        | 0.812        | 0.863        | 0.595        | 0.681        |
| p-value*        |          |                                                               |              |              |              |              |              |              |
| Lymph node      |          |                                                               | 0.96         | 0.85         | 0.46         | 0.70         | 0.49         | 0.72         |
| involvement     |          |                                                               | 0.96         | 0.88         | 0.42         | 0.60         | 0.46         | 0.71         |
| N0 (144)        |          |                                                               | 0.777        | 0.726        | 0.498        | 0.146        | 0.571        | 0.951        |
| N1&2&3 (103)    |          |                                                               |              |              |              |              |              |              |
| p-value*        |          |                                                               | 0.95         | 0.81         | 0.41         | 0.66         | 0.47         | 0.72         |
| Ki67            |          |                                                               | 0.96         | 0.88         | 0.44         | 0.68         | 0.49         | 0.71         |
| Ki67 < 20% (95) |          |                                                               | 0.206        | 0.440        | 0.965        | 0.575        | 0.436        | 0.515        |
| Ki67 > 20% (154)|          |                                                               | 0.777        | 0.726        | 0.498        | 0.146        | 0.571        | 0.951        |
| p-value*        |          |                                                               | 0.95         | 0.87         | 0.43         | 0.74         | 0.50         | 0.71         |
| ER              |          |                                                               | 0.96         | 0.86         | 0.44         | 0.66         | 0.47         | 0.71         |
| ER negative (52)|          |                                                               | 0.593        | 0.707        | 0.714        | 0.349        | 0.238        | 0.566        |
| p-value*        |          |                                                               |              |              |              |              |              |              |
| PR              |          |                                                               | 0.97         | 0.85         | 0.43         | 0.74         | 0.52         | 0.70         |
| PR negative (68)|          |                                                               | 0.96         | 0.86         | 0.44         | 0.64         | 0.47         | 0.72         |
| p-value*        |          |                                                               |              |              |              |              |              |              |
| HER2            |          |                                                               | 0.95         | 0.86         | 0.43         | 0.64         | 0.48         | 0.71         |
| HER2 negative (191)|        |                                                               | 0.97         | 0.87         | 0.46         | 0.75         | 0.49         | 0.72         |
| p-value*        |          |                                                               | 0.208        | 0.26         | 0.627        | 0.408        | 0.996        | 0.3          |
| HER2 positive (62)|          |                                                               | 0.548        | 0.307        | 0.399        | 0.192        | 0.056        | 0.437        |
| Triple-negative |          |                                                               |              |              |              |              |              |              |
| Tumor size      |          |                                                               | 0.93         | 0.82         | 0.41         | 0.68         | 0.51         | 0.60         |
| T0&1 (158)      |          |                                                               | 0.97         | 0.87         | 0.44         | 0.66         | 0.48         | 0.72         |
| T2&3&4 (91)     |          |                                                               | 0.110        | 0.544        | 0.254        | 0.823        | 0.530        | 0.031        |
| Non-triple-negative (220)| |                                                               |              |              |              |              |              |              |
| p-value*        |          |                                                               |              |              |              |              |              |              |

*Mann-Whitney U test. Bold values indicated p < 0.05.
B cell lymphoma, especially in subtype I, which displayed poorer overall survival time and progression-free survival time than those in subtype II. Nagashima et al. (Nagashima et al., 2018) found significantly higher expression of ISYNA1 in high-grade gliomas than in primary central nervous system lymphomas. Cheng et al. (Cheng et al., 2016) showed that RAD51B mRNA expression was

| Characteristics | Group (n) | Median of methylation levels |
|-----------------|-----------------|-------------------------------|
| | ISYNA1_CpG_1 | ISYNA1_CpG_2 | ISYNA1_CpG_3 | ISYNA1_CpG_4 | ISYNA1_CpG_5 | ISYNA1_CpG_6 | ISYNA1_CpG_7 | ISYNA1_CpG_9 |
| Tumor stage | Stage 0&I (116) | 0.85 | 0.67 | 0.87 | 0.90 | 0.32 | 0.57 | 0.53 |
| | Stage II&III (131) | 0.86 | 0.66 | 0.87 | 0.86 | 0.34 | 0.56 | 0.57 |
| | p-value* | 0.147 | 0.225 | 0.953 | 4.12E−04 | 0.531 | 0.966 | 0.047 |
| Tumor size | T0&1 (158) | 0.85 | 0.66 | 0.87 | 0.89 | 0.33 | 0.57 | 0.55 |
| | T2&3&4 (91) | 0.86 | 0.67 | 0.87 | 0.85 | 0.34 | 0.54 | 0.56 |
| | p-value* | 0.353 | 0.868 | 0.852 | 0.003 | 0.868 | 0.481 | 0.188 |
| Lymph node involvement | N0 (144) | 0.85 | 0.67 | 0.87 | 0.89 | 0.33 | 0.56 | 0.55 |
| | N1&2&3 (103) | 0.86 | 0.66 | 0.88 | 0.86 | 0.34 | 0.58 | 0.57 |
| | p-value* | 0.119 | 0.106 | 0.461 | 0.019 | 0.447 | 0.287 | 0.155 |
| Ki67 | \(\text{Ki67} \leq 20\%\) (96) | 0.84 | 0.66 | 0.87 | 0.88 | 0.33 | 0.56 | 0.54 |
| | \(\text{Ki67} > 20\%\) (154) | 0.86 | 0.67 | 0.87 | 0.87 | 0.33 | 0.56 | 0.57 |
| | p-value* | 0.120 | 0.883 | 0.544 | 0.477 | 0.872 | 0.780 | 0.508 |
| ER | ER negative (52) | 0.86 | 0.68 | 0.88 | 0.87 | 0.31 | 0.58 | 0.58 |
| | ER positive (200) | 0.86 | 0.66 | 0.87 | 0.88 | 0.33 | 0.56 | 0.55 |
| | p-value* | 0.385 | 0.347 | 0.793 | 0.592 | 0.875 | 0.770 | 0.316 |
| PR | PR negative (68) | 0.86 | 0.68 | 0.88 | 0.87 | 0.32 | 0.57 | 0.57 |
| | PR positive (184) | 0.86 | 0.66 | 0.87 | 0.88 | 0.33 | 0.56 | 0.55 |
| | p-value* | 0.605 | 0.173 | 0.749 | 0.958 | 0.995 | 0.725 | 0.445 |
| HER2 | HER2 negative (191) | 0.86 | 0.66 | 0.87 | 0.88 | 0.33 | 0.56 | 0.55 |
| | HER2 positive (62) | 0.85 | 0.68 | 0.89 | 0.88 | 0.33 | 0.58 | 0.56 |
| | p-value* | 0.877 | 0.402 | 0.129 | 0.957 | 0.89 | 0.412 | 0.784 |
| Triple-negative | Non-triple-negative (220) | 0.89 | 0.67 | 0.86 | 0.87 | 0.31 | 0.59 | 0.58 |
| | p-value* | 0.056 | 0.958 | 0.685 | 0.463 | 0.873 | 0.975 | 0.274 |

*p-Mann-Whitney U test. Bold values indicated \(p < 0.05\).
| Characteristics       | Group (N) | Median of methylation levels |
|-----------------------|-----------|-----------------------------|
|                       | RAD51B.  |
|                       | CpG_1.2  | RAD51B.  |
|                       | CpG_3    | RAD51B.  |
|                       | CpG_4    | RAD51B.  |
|                       | CpG_6    | RAD51B.  |
|                       | CpG_7.8/ |
|                       | cg13803234| RAD51B.  |
|                       | CpG_9    | RAD51B.  |
|                       | CpG_10   | RAD51B.  |
|                       | CpG_11   | RAD51B.  |
|                       | CpG_12   | RAD51B.  |
|                       | CpG_13.14/|
|                       | cg10975863| RAD51B.  |
|                       | CpG_15   | RAD51B.  |
|                       | CpG_16   | RAD51B.  |
|                       | CpG_18   | RAD51B.  |
|                       | CpG_20   |         |
| Tumor stage           | Stage 0&I (116) | 0.65 | 0.96 | 0.68 | 0.64 | 0.855 | 0.575 | 0.37 | 0.32 | 0.365 | 0.48 | 0.34 | 0.25 | 0.50 | 0.64 |
|                       | Stage II (131)  | 0.65 | 0.96 | 0.67 | 0.65 | 0.84 | 0.58 | 0.39 | 0.31 | 0.36 | 0.47 | 0.34 | 0.26 | 0.49 | 0.65 |
| p-value*              | 0.377     | 0.475 | 0.231 | 0.275 | 0.225 | 0.918 | 0.803 | 0.497 | 0.943 | 0.722 | 0.986 | 0.742 | 0.432 | 0.275 |
| Tumor size            | T0&1 (158) | 0.65 | 0.96 | 0.66 | 0.64 | 0.85 | 0.57 | 0.37 | 0.32 | 0.35 | 0.47 | 0.34 | 0.25 | 0.50 | 0.64 |
|                       | T2&3&4 (91) | 0.65 | 0.96 | 0.68 | 0.67 | 0.84 | 0.58 | 0.40 | 0.32 | 0.37 | 0.48 | 0.34 | 0.27 | 0.50 | 0.67 |
| p-value*              | 0.620     | 0.513 | 0.349 | 0.296 | 0.413 | 0.227 | 0.204 | 0.382 | 0.192 | 0.163 | 0.317 | 0.804 | 0.992 | 0.296 | |
| Lymph node involvement| N0 (144)  | 0.65 | 0.96 | 0.68 | 0.69 | 0.86 | 0.58 | 0.39 | 0.32 | 0.37 | 0.48 | 0.35 | 0.26 | 0.51 | 0.69 |
|                       | N1&2&3 (103)| 0.64 | 0.96 | 0.64 | 0.62 | 0.84 | 0.56 | 0.37 | 0.30 | 0.35 | 0.47 | 0.32 | 0.25 | 0.47 | 0.62 |
| p-value*              | 0.098     | 0.931 | 0.076 | 0.001 | 0.053 | 0.420 | 0.325 | 0.127 | 0.251 | 0.230 | 0.053 | 0.640 | 0.088 | 0.001 | |
| Ki67                  | Ki67 ≤ 20% (94) | 0.65 | 0.96 | 0.68 | 0.69 | 0.86 | 0.57 | 0.39 | 0.32 | 0.35 | 0.47 | 0.35 | 0.28 | 0.50 | 0.63 |
|                       | Ki67 >20% (154)| 0.65 | 0.96 | 0.67 | 0.67 | 0.84 | 0.58 | 0.38 | 0.32 | 0.37 | 0.48 | 0.33 | 0.25 | 0.49 | 0.67 |
| p-value*              | 0.915     | 0.150 | 0.822 | 0.313 | 0.882 | 0.757 | 0.804 | 0.783 | 0.817 | 0.950 | 0.262 | 0.664 | 0.750 | 0.313 | |
| ER                    | Negative (52) | 0.64 | 0.96 | 0.68 | 0.69 | 0.86 | 0.57 | 0.38 | 0.31 | 0.36 | 0.47 | 0.34 | 0.26 | 0.49 | 0.64 |
|                       | Positive (203)| 0.66 | 0.97 | 0.67 | 0.67 | 0.86 | 0.60 | 0.40 | 0.34 | 0.38 | 0.50 | 0.34 | 0.25 | 0.51 | 0.67 |
| p-value*              | 0.008     | 0.043 | 0.406 | 0.375 | 0.028 | 0.099 | 0.357 | 0.083 | 0.406 | 0.224 | 0.903 | 0.569 | 0.183 | 0.375 | |
| PR                    | Negative (68) | 0.64 | 0.96 | 0.68 | 0.64 | 0.84 | 0.57 | 0.37 | 0.31 | 0.35 | 0.46 | 0.34 | 0.26 | 0.49 | 0.64 |
|                       | Positive (184)| 0.68 | 0.96 | 0.67 | 0.67 | 0.86 | 0.59 | 0.40 | 0.33 | 0.38 | 0.53 | 0.34 | 0.25 | 0.52 | 0.67 |
| p-value*              | 0.035     | 0.080 | 0.497 | 0.219 | 0.111 | 0.176 | 0.200 | 0.074 | 0.247 | 0.056 | 0.561 | 0.652 | 0.079 | 0.219 | |
| HER2                  | Negative (190)| 0.65 | 0.96 | 0.67 | 0.65 | 0.84 | 0.58 | 0.39 | 0.32 | 0.36 | 0.47 | 0.34 | 0.27 | 0.50 | 0.65 |
|                       | Positive (62)| 0.65 | 0.96 | 0.68 | 0.65 | 0.88 | 0.57 | 0.37 | 0.32 | 0.36 | 0.49 | 0.32 | 0.25 | 0.50 | 0.65 |
| p-value*              | 0.756     | 0.582 | 0.260 | 0.659 | 0.191 | 0.946 | 0.582 | 0.974 | 0.890 | 0.586 | 0.824 | 0.480 | 0.589 | 0.659 | |
| Triple-negative       | Triple- |
|                       | negative (32) | 0.64 | 0.96 | 0.68 | 0.64 | 0.84 | 0.57 | 0.37 | 0.31 | 0.35 | 0.47 | 0.33 | 0.25 | 0.49 | 0.64 |
|                       | Non-triple- |
|                       | negative (220)| 0.67 | 0.98 | 0.65 | 0.74 | 0.92 | 0.61 | 0.46 | 0.38 | 0.41 | 0.54 | 0.39 | 0.26 | 0.58 | 0.74 |
| p-value*              | 0.006     | 0.038 | 0.391 | 0.083 | 0.025 | 0.059 | 0.017 | 0.003 | 0.076 | 0.067 | 0.195 | 0.306 | 0.034 | 0.083 | |

*Mann-Whitney U test. Bold values indicated p < 0.05.
significantly up-regulated in gastric cancer tissues and high level of RAD51B protein was correlated with advanced stage, aggressive differentiation and lymph node metastasis. However, so far there are no reports about the correlation between CD160, ISYNA1 as well as RAD51B and clinical characteristics of BC, especially in the aspect of DNA methylation. Our findings suggested that aberrant methylation of CD160, ISYNA1 and RAD51B in blood might be important predictors for the development of BC and could be prognosis biomarkers for BC. Unfortunately, the samples of fresh blood or RNA are not available in this study. Whether the altered methylation of CD160, ISYNA1 and RAD51B could modulate the gene expression and biological function requires further investigations in future. DNA methyltransferases (DNMTs) are responsible for the establishment and maintenance of DNA methylation (Edwards et al., 2017; Lyko, 2018). Lysine demethylases (KDMs) are responsible for the demethylation of histone H3 and non-histone substrates, and have been implicated in diverse genomic processes, such as epigenetic gene regulation, DNA damage response, DNA replication, regulation of heterochromatin structure and maintenance of global DNA methylation (Dimitrova et al., 2015; Arifuzzaman et al., 2020). DNMTs and KDMs (like KDM4 and KDM5) are often deregulated and play important roles in malignant tumors (Pich et al., 2019; Hoang and Rui, 2020; Lee et al., 2020; Sterling et al., 2020). Therefore, it would be interesting to investigate the expression status of key DNMTs and KDMs, and analyze their relationship with the altered methylation levels of CD160, ISYNA1 and RAD51B in the peripheral blood of BC cases and controls, which could further validate the results presented here. In addition, methylation of cytosine in CpG dinucleotides and histone lysine and arginine residues is a chromatin modification that regulates genome integrity, replication, and accessibility (Rose and Klose, 2014; Li et al., 2021). Genome-wide profiling of CpG methylation revealed a strong correlation between DNA methylation and histone methylation, including a positive correlation with histone H3K9 methylation and a negative correlation with H3K4 methylation (Meisner et al., 2008). A meta-analysis of whole-genome bisulfite sequencing and ChIP-seq datasets from 35 human cell types also showed that CpG methylation is negatively correlated with H3K4 and H3K27 methylation and positively correlated with H3K9 and H3K36 methylation (Fu et al., 2020). In addition, several evidences have disclosed an intimate interaction between DNA and histone methylation in the development of human diseases. Hypermethylation in promoter CpG islands in cancers are marked by H3K27me3 in embryonic or tissue stem/progenitor cells (Ohm et al., 2007; Schlesinger et al., 2007; Widschwendter et al., 2007). Duncan et al. (Duncan et al., 2020) showed that the ratio of H3K27me3 to H3K4me3 at bivalent promoters can predict the likelihood of cancer-associated DNA hypermethylation. Stoll et al. (Stoll et al., 2018) demonstrated that DNA methylation and histone methylation are involved in the function of vascular cells in response to environmental stresses. Therefore, the data relating to histone methylation status could help to interpret DNA methylation status of CpG sites, which are not available in the study and need further investigation in the future studies.

Moreover, due to the limitation of the case-control studies with relatively small samples, large-scale prospective studies are warranted to further validate our results and identify if such DNA methylation signatures could bear on the diagnosis and/or prognosis of patients with BC.

CONCLUSION

This study provided further evidence for the association between altered methylation of CD160, ISYNA1 and RAD51B in blood and BC. In addition, we suggested the influence of genetic background, life style, age, stage and receptor status of tumor as confounders for the DNA methylation. Notably, we highlighted that the epigenetic biomarkers in one ethnic group warrant population-based validation before its application in another ethnic group.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Materials, further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Ethics Committee of Nanjing Medical University, the Cancer Hospital of Chinese Academy of Medical Science and Jiangsu Province Hospital of Chinese Medicine. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

RY and CL designed the experiment and wrote the manuscript. XZ, JJ, and QZ performed all the experiments and analyzed the results. LL, QY, TX, WG, and FM provided the biological samples and informed consent to participate in this study.

FUNDING

This work was funded by the National Natural Science Foundation of China (Grant Nos. 81803303 and 81874122), the Natural Science Foundation of Jiangsu Province (Grant No. BK20180674), the CAMS Initiative for Innovative Medicine (Grant No. 2017-12M-3-004) and the Jiangsu Funding (WSW-009).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2022.927519/full#supplementary-material
REFERENCES

Abdel, Q. A., Yu, B. P., Chung, H. Y., Jung, H. A., and Choi, J. S. (2017). Epigenetic Modifications of Gene Expression by Lifestyle and Environment. Arch. Pharm. Res. 40, 1219–1237. doi:10.1007/s12277-017-0973-3

Ariuzzaman, S., Khatun, M. R., and Khatun, R. (2020). Emerging of Lysine Demethylases (KDMs): From Pathophysiological Insights to Novel Therapeutic Opportunities. Biomed. Pharmacother. 129, 110392. doi:10.1016/j.biopharm.2020.110392

Belinsky, S. A., Nikula, K. J., Palmasino, W. A., Michels, R., Saccomanno, G., Gabrielison, E., et al. (1998). Aberrant Methylatation of P16 INK4a Is an Early Event in Lung Cancer and a Potential Biomarker for Early Diagnosis. Proc. Natl. Acad. Sci. U.S.A. 95, 11891–11896. doi:10.1073/pnas.95.20.11891

Berry, D. A., Cronin, K. A., Plevrati, S., Clarke, L., Zelen, M., et al. (2005). Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer. N. Engl. J. Med. 353, 1784–1792. doi:10.1056/nejmoa050518

Bozorgmehr, N., Okoye, I., Oyegbami, O., Xu, L., Fontaine, A., Cox-Kennett, N., et al. (2021). Expanded Antigen-Experience CD160+CD8 Effector T Cells Exhibit Impaired Effector Functions in Chronic Lymphocytic Leukemia. J. Immunother. Cancer 9. doi:10.1136/jitc-2020-001839

Brennan, K., Garcia-Closas, M., Orr, N., Fletcher, O., Jones, M., Ashworth, A., et al. (2012). Intragenic ATM Methylation in Peripheral Blood DNA as a Biomarker of Breast Cancer Risk. Cancer Res. 72, 2304–2313. doi:10.1158/0008-5472.can-11-3157

Cappetta, M., Fernandez, L., Brignoni, L., Artagaveytia, N., Bonilla, C., López, M., et al. (2015). Dietary Modlifying the BRCA1 Promoter Methylation in Peripheral Blood Cells Is Associated with BRCA1 Promoter Methylation. Cancer Res. Treat. 47, 129, 69–77. doi:10.1007/s10527-014-9898-8

Chabot, S., Jabrane-Ferrat, N., Bigot, K., Tabiasco, J., Provost, A., Golzio, M., et al. (2013). Potential Role and Therapeutic Interests of 5-Methylcytosine in Metastatic Breast Cancer. Tumor Biol. 34, 1007–1017. doi:10.1007/s13277-013-1568-8

Cheng, Y., Yang, B., Xi, Y., and Chen, X. (2016). Rad51b as a Potential Biomarker of Breast Cancer. J. Genet. Genomics 43, 361–372. doi:10.1016/j.jgg.2016.04.006

Horvath, S., Zhang, Y., Langfelder, P., Kahn, R. S., Zonderman, A. B., et al. (2013). Epigenetic Alterations in the Gastrointestinal Tract: Current and Emerging Use for Biomarkers of Cancer. Epigenetics 8, 1192–1206. doi:10.4161/ebc.24280.8.7

Hoang, N.-M., and Rui, L. (2020). DNA Methyltransferases in Hematological Malignancies. J. Genet. Genomics 47, 361–372. doi:10.1016/j.jgg.2020.04.006

Horvath, S., Zhang, Y., Langfelder, P., Kahn, R. S., Boks, M. P., Van Eijk, K., et al. (2012). Aging Effects on DNA Methylation Modules in Human Brain and Blood Tissue. Genome Biol. 13, R97. doi:10.1186/gb-2012-13-10-r97

Hsu, L., Lin, H., Li, D., Li, L., and Liu, Z. (2012). Mining Functional Gene Modules Linked with Rheumatoid Arthritis Using a SNP-SNP Network. Genomics, Proteomics Bioinforma. 10, 23–34. doi:10.4161/gpbi.22299.10.03003.2

Huo, D., Hu, H., Rie, S. K., Gamazon, E. R., Cherniack, A. D., Liu, J., et al. (2017). Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in the Cancer Genome Atlas. JAMA Oncol. 3, 1654–1662. doi:10.1001/jamaoncol.2017.0595

Independent UK Panel on Breast Cancer Screening (2012). The Benefits and Harms of Breast Cancer Screening: an Independent Review. Lancet 380, 1778–1786. doi:10.1016/S0140-6736(12)61611-0

Iwamoto, T., Yamamoto, N., Taguchi, T., Tamaki, Y., and Nugochi, S. (2011). BRCA1 Promoter Methylation in Peripheral Blood Cells Is Associated with Increased Risk of Breast Cancer with BRCA1 Promoter Methylation. Breast Cancer Res. Treat. 129, 69–77. doi:10.1007/s10549-010-1188-1

Johanning, G. L., Heimburger, D. C., and Pyathilahke, C. J. (2002). DNA Methylation and Diet in Cancer. J. Nutr. 132, 3818–38185. doi:10.1093/jn/132.12.3814s

Jones, P. A., and Baylin, S. B. (2002). The Fundamental Role of Epigenetic Events in Cancer. Nat. Rev. Genet. 3, 415–428. doi:10.1038/nrg816

Jung, S.-E., Shin, K.-J., and Lee, H. Y. (2017). DNA Methylation-Based Age Prediction from Various Tissues and Body Fluids. BMB Rep. 50, 546–553. doi:10.5483/bmbrep.2017.50.11.175

Koguchi, T., Tamakawa, C., Mori, I., Kojima, Y., and Matsuda, K. (2016). Regulation of Myo-Inositol Biosynthesis by P53-ISYNA1 Pathway. Int. J. Oncol. 48, 2415–2424. doi:10.3892/ijo.2016.3456

Kurreeman, F. A. S., Stahl, E. A., Okada, Y., Liao, K., Diogo, D., Raychaudhuri, S., et al. (2012). Use of a Multiethnic Approach to Identify Rheumatoid- Arthritis-
Xue, F., Willett, W. C., Rosner, B. A., Hankinson, S. E., and Michels, K. B. (2011). Cigarette Smoking and the Incidence of Breast Cancer. *Arch. Intern Med.* 171, 125–133. doi:10.1001/archinternmed.2010.503

Yang, Y., Wu, L., Shu, X.-O., Cai, Q., Shu, X., Li, B., et al. (2020). Genetically Predicted Levels of DNA Methylation Biomarkers and Breast Cancer Risk: Data from 228,951 Women of European Descent. *J. Natl. Cancer Inst.* 112, 295–304. doi:10.1093/jnci/djz109

Yin, Y., Lei, S., Li, L., Yang, X., Yin, Q., Xu, T., et al. (2022). RPTOR Methylation in the Peripheral Blood and Breast Cancer in the Chinese Population. *Genes Genom* 44, 435–443. doi:10.1007/s13258-021-01182-0

Yu, H., Peng, S., Han, S., Chen, X., Lyu, Q., and Lei, T. (2021). Distinct Molecular Subtypes of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP Are Associated with Different Clinical Outcomes and Molecular Mechanisms. *Biomed. Res. Int.* 2021, 5514726. doi:10.1155/2021/5514726

Zhang, F. F., Cardarelli, R., Carroll, J., Fulda, K. G., Kaur, M., Gonzalez, K., et al. (2011). Significant Differences in Global Genomic DNA Methylation by Gender and Race/ethnicity in Peripheral Blood. *Epigenetics* 6, 623–629. doi:10.4161/epi.6.5.15335

Zhu, B., Mukherjee, A., Machiela, M. J., Song, L., Hua, X., Shi, J., et al. (2016). An Investigation of the Association of Genetic Susceptibility Risk with Somatic Mutation Burden in Breast Cancer. *Br. J. Cancer* 115, 752–760. doi:10.1038/bjc.2016.223

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

*Copyright © 2022 Liu, Zhou, Jin, Zhu, Li, Yin, Xu, Gu, Ma and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*